Introduction: Surgeries that spare the adrenal cortex during adrenalectomy have profound justification. Indications for this type of surgery are fairly strict, and more than 30 years of observations continuously verify the results of the procedure.

Material And Methods: Of a total of 650 adrenalectomies, 22 (3.4%) were adrenal cortex-sparing surgeries. There were 16 women and six men in this group. In 10 cases, surgery was performed for pheochromocytoma, eight cases involved Conn's syndrome, and in four cases - paragangliomas located in the para-adrenal region. Secretory activity was identified in all cases.

Results: Laparoscopic partial adrenalectomy was performed in 20 patients. Conversion to open laparotomy was necessary in two cases. In patients after bilateral resection of pheochromocytoma surgery, glucocorticoids were supplemented for six weeks. No significant surgical complications were observed in this group.

Conclusions: Partial adrenalectomy for minor lesions should be a much more commonly utilised treatment method (of choice). Where bilateral adrenalectomy is necessary, a sparing procedure on one side protects patients from the need for hormonal substitution. The remaining part of the adrenal gland undertakes satisfactory secretory function after six weeks at the latest.

Download full-text PDF

Source
http://dx.doi.org/10.5603/EP.a2020.0033DOI Listing

Publication Analysis

Top Keywords

partial adrenalectomy
8
adrenal-sparing surgery
4
surgery hormonally
4
hormonally active
4
active tumour
4
tumour single-centre
4
single-centre experience
4
experience introduction
4
introduction surgeries
4
surgeries spare
4

Similar Publications

Clear cell renal cell carcinoma is the predominant subtype of kidney cancer. With distant metastasis, the overall survival rate for patients with renal cell carcinoma decreases significantly compared to localized disease. However, pembrolizumab plus axitinib combination is safe and improves long-term survival.

View Article and Find Full Text PDF

Percutaneous microwave ablation for aldosterone-producing adenoma.

J Vasc Interv Radiol

December 2024

Department of Radiology, Tianjin Medical University General Hospital, Anshan Road 154#, Heping District, Tianjin, 300052, China. Electronic address:

Thirty-five patients diagnosed with aldosterone-producing adenomas underwent CT-guided percutaneous microwave ablation (MWA). Comparisons of aldosterone-to-renin ratio (ARR), potassium level, blood pressure (BP), and medications were performed preoperatively, postoperatively, and at the latest follow-up examination. The outcome assessment was based on the primary aldosteronism surgical outcome (PASO) Standards.

View Article and Find Full Text PDF

Background: Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing's syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective. Patients unsuitable for bilateral adrenalectomy (BA) have dismal outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Primary aldosteronism (PA) is a major cause of secondary hypertension, and a study shows that unilateral adrenalectomy can effectively cure it, with findings from a 24-year period at a UK center.
  • The study analyzed data from 82 patients, focusing on biochemical, radiological, and surgical outcomes, and reported a high rate of clinical and biochemical success after surgery.
  • Results indicated that 88% of patients experienced clinical benefits and nearly all achieved biochemical cures, with these positive outcomes sustained for at least five years post-surgery.
View Article and Find Full Text PDF

Early Screening and Identification of an Asymptomatic Pheochromocytoma in a Child with Von Hippel-Lindau: A Case Report.

Case Rep Oncol

November 2024

Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.

Introduction: Von Hippel-Lindau (VHL) is a diagnosis that leads to increased risk of tumor development over the course of a patient's lifetime. Patients with VHL undergo screening for multiple tumor types, including pheochromocytomas (PCCs). There is variability among the different international guidelines regarding the age to begin PCC screening, with most suggesting 5 years for screening initiation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!